LightNews LightNews
amandapinho.bsky.social
@amandapinho.bsky.social
14 followers 38 following 0 posts
Posts Replies Media Videos
Reposted
rolandoug.bsky.social
Costa Rica avanzará en 2025 con la aprobación ahora de #Nirsevimab como complemento a la ya aprobada #inmunizaciónmaterna contra #VRS. Esperamos tiempos mejores en 🇨🇷 a la luz de la evidencia mundial ya disponible. #vrscostarica #vrslatam #stoprsv #pedsidsky
www.teletica.com/nacional/ant...
Anticuerpo para proteger a bebés de virus sincitial se usará en Costa Rica | Teletica
En su última sesión, la Comisión Nacional de Vacunación y Epidemiología avaló el uso de este medicamento.
www.teletica.com
December 17, 2024 at 10:55 PM
Reposted
aboutscience.bsky.social
This study assessed #RSV impact in #Italy and the benefits of #nirsevimab. Current strategies protect only high-risk infants, but nirsevimab could cut cases, complications, and costs in their first season.

journals.aboutscience.eu/index.php/gr...
February 3, 2025 at 9:43 AM
Reposted
rolandoug.bsky.social
1) 2024 termina hoy dejándonos uno de los estudios de > impacto en prevención con #Nirsevimab contra #VRS Virus Respiratorio Sincitial, el estudio #Nirse-Gal via #lancetid y liderado por Federico Martinon-Torres y cols. Impacto fantástico. #stoprsv #pedsky #idsky #pedsidsky
doi.org/10.1016/S147...
Redirecting
doi.org
December 31, 2024 at 7:17 PM
Reposted
castltrastondrs.bsky.social
#Medsky🧪 #IDsky #pedsky #publichealth This full RSV season analysis confirms that #nirsevimab reduced infant hospitalisation for #RSV-related LRTI, RSV-related LRTI requiring oxygen, and all-cause #bronchiolitis or #bronchitis,

www.thelancet.com/journals/lan...
Full 2023–24 season results of universal prophylaxis with nirsevimab in Galicia, Spain: the NIRSE-GAL study
In April, 2024, we reported on mid-season findings from NIRSE-GAL, a population-based longitudinal study on the effectiveness of universal nirsevimab prophylaxis against respiratory syncytial virus (RSV) in infants aged 0–24 months in Galicia, Spain.1 Our early findings aligned with other interim real-world studies on the considerable effectiveness of nirsevimab in preventing RSV-related hospitalisations for lower respiratory tract infections (LRTIs).2 The immunisation campaign in Galicia (which ran from Sept 25, 2023, to March 31, 2024) is described elsewhere.
www.thelancet.com
December 12, 2024 at 8:00 AM
Reposted
iballesty.bsky.social
Influenza remains high in Ireland, but cases and hospitalisations have decreased. RSV and COVID-19 activity is low. XEC is the dominant SARS-CoV-2 variant. #Influenza #RSV #COVID19
https://buff.ly/3WPiLJK
February 9, 2025 at 10:53 AM
Reposted
eurosurveillance.org
In 2023, Spain started recommending systematic nirsevimab administration to all infants born or entering their first #respiratory #virus season

Núñez et al. look at effectiveness of nirsevimab in preventing hospital admission due to #RSV infection in the 2023/24 season

🗞️ bit.ly/EUS305RSV

🧪😷🩺 🛟
Image showing the Key public health message for this paper. What did you want to address in this study and why? The administration of a long-acting monoclonal antibody, such as nirsevimab, in a population-wide immunisation campaign has no precedent in public health practice. Assessing the effectiveness of this preventive intervention against severe RSV infection in children in their first respiratory virus season is of utmost importance to inform future recommendations. What have we learnt from this study? The risk of hospitalisation for an RSV infection was reduced by around 80% in children under 6 months who received nirsevimab immunisation. Effectiveness was similar for intensive care admission and need of mechanical ventilation, as well as for different RSV subgroups, while effectiveness was slightly lower for children born pre-term, with low birthweight, or from multiple pregnancy. What are the implications of your findings for public health? Our results support nirsevimab administration to all children born during or entering their first respiratory virus season and show that the entire newborn population greatly benefited from this intervention, including children with comorbidities or low birthweight and those born pre-term or from multiple pregnancy.
February 10, 2025 at 12:41 PM
Reposted
ukhsa.bsky.social
NEW #UKHSAVirusWatch: Data shows a continued decrease in positive tests for #Flu, #COVID19 has remained at baseline levels and #RSV activity decreased but continues to circulate at baseline levels. 📉🤧
Positive tests (%) for Flu, data from 12 February 2024 to 09 February 2025. The graph shows a sharp spark from November to December 2024, with a decrease happening in late December through to February. Positive tests (%) for COVID-19, data from 12 February 2024 to 09 February 2025. The graph shows a decline from October 2024 to January 2024, then stabilisation since. Positive tests (%) for RSV, data from 12 February to 09 February 2025. The graph shows a sharp spark from October to November and December 2024, with a decrease from November to January 2024.
February 13, 2025 at 4:48 PM